These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27224546)

  • 1. Rac GTPase regulation of 3D invasion in neuroblastomas lacking MYCN amplification.
    Mitchell CB; O'Neill GM
    Cell Adh Migr; 2017 Jan; 11(1):68-79. PubMed ID: 27224546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule targeting of the actin associating protein tropomyosin Tpm3.1 increases neuroblastoma cell response to inhibition of Rac-mediated multicellular invasion.
    Mitchell CB; Stehn JR; O'Neill GM
    Cytoskeleton (Hoboken); 2018 Jul; 75(7):307-317. PubMed ID: 29752871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
    Hallett RM; Seong AB; Kaplan DR; Irwin MS
    Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.
    Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ
    Oncotarget; 2015 Jun; 6(17):15510-23. PubMed ID: 25860940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keratoepithelin reverts the suppression of tissue factor pathway inhibitor 2 by MYCN in human neuroblastoma: a mechanism to inhibit invasion.
    Becker J; Volland S; Noskova I; Schramm A; Schweigerer LL; Wilting J
    Int J Oncol; 2008 Jan; 32(1):235-40. PubMed ID: 18097563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma.
    Ferrucci F; Ciaccio R; Monticelli S; Pigini P; di Giacomo S; Purgato S; Erriquez D; Bernardoni R; Norris M; Haber M; Milazzo G; Perini G
    Biochim Biophys Acta Gene Regul Mech; 2018 Mar; 1861(3):235-245. PubMed ID: 29408445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.
    Fabian J; Opitz D; Althoff K; Lodrini M; Hero B; Volland R; Beckers A; de Preter K; Decock A; Patil N; Abba M; Kopp-Schneider A; Astrahantseff K; Wünschel J; Pfeil S; Ercu M; Künkele A; Hu J; Thole T; Schweizer L; Mechtersheimer G; Carter D; Cheung BB; Popanda O; von Deimling A; Koster J; Versteeg R; Schwab M; Marshall GM; Speleman F; Erb U; Zoeller M; Allgayer H; Simon T; Fischer M; Kulozik AE; Eggert A; Witt O; Schulte JH; Deubzer HE
    Oncotarget; 2016 Oct; 7(41):66344-66359. PubMed ID: 27572323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
    O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
    BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
    Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
    Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXR2 Stabilizes MYCN Protein and Identifies Non-
    Schmitt-Hoffner F; van Rijn S; Toprak UH; Mauermann M; Rosemann F; Heit-Mondrzyk A; Hübner JM; Camgöz A; Hartlieb S; Pfister SM; Henrich KO; Westermann F; Kool M
    J Clin Oncol; 2021 Oct; 39(29):3217-3228. PubMed ID: 34110923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Targeting of
    Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H
    Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk
    Wei JS; Kuznetsov IB; Zhang S; Song YK; Asgharzadeh S; Sindiri S; Wen X; Patidar R; Najaraj S; Walton A; Auvil JMG; Gerhard DS; Yuksel A; Catchpoole D; Hewitt SM; Sondel PM; Seeger R; Maris JM; Khan J
    Clin Cancer Res; 2018 Nov; 24(22):5673-5684. PubMed ID: 29784674
    [No Abstract]   [Full Text] [Related]  

  • 13. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
    Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA Ligase 4 Contributes to Cell Proliferation against DNA-PK Inhibition in
    Ando K; Suenaga Y; Kamijo T
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MYCN enigma: significance of MYCN expression in neuroblastoma.
    Tang XX; Zhao H; Kung B; Kim DY; Hicks SL; Cohn SL; Cheung NK; Seeger RC; Evans AE; Ikegaki N
    Cancer Res; 2006 Mar; 66(5):2826-33. PubMed ID: 16510605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.
    Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ
    Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NEDD9 regulates 3D migratory activity independent of the Rac1 morphology switch in glioma and neuroblastoma.
    Zhong J; Bach CT; Shum MS; O'Neill GM
    Mol Cancer Res; 2014 Feb; 12(2):264-73. PubMed ID: 24337070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
    Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
    Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
    Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
    Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.